Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
Marketing Status approved; investigational
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 0832-1120; 65089-0050; 43598-304; 49884-418; 63629-8455; 63629-9310; 0591-2925; 38779-2936; 43647-568; 43742-1436; 73774-014; 76003-1083; 43742-1242; 0245-0871; 62332-552; 70700-112; 76420-685; 76420-687; 76420-699; 24979-130; 45802-610; 0051-8462; 64380-151; 68180-943; 69097-363; 0591-2363; 0603-7831; 0009-5020; 44132-006; 49452-7658; 64025-0010; 45802-281; 0245-0872; 0023-5992; 63629-2125; 64380-152; 66887-001; 0591-2114; 0591-2924; 0591-2926; 0591-3216; 0832-1121; 51927-0267; 70492-002; 76420-684; 0009-0074; 12875-8248; 22552-0009; 49452-7652; 60592-721; 60870-0251; 16714-967; 17139-562; 63629-2124; 68180-941; 44132-008; 48087-0113; 51552-0029; 42667-5511; 63481-183; 63629-2352; 69238-1013; 0591-3217; 0591-3524; 38779-0163; 38779-2598; 82393-113; 24979-078; 45802-366; 66887-004; 51552-0564; 62991-2150; 76420-686; 16714-969; 45802-754; 49884-510; 62332-488; 69339-158; 0591-2921; 49452-7657; 16714-968; 0023-5990
UNII 3XMK78S47O
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004---
Diabetes mellitus05.06.01.001; 14.06.01.001---
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.000091%-
Diplopia06.02.06.002; 17.17.01.005---
Discomfort08.01.08.003---
Dissociation19.14.01.002---
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Drug ineffective08.06.01.006---
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Dysphonia17.02.08.004; 19.19.03.002; 22.12.03.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Ear disorder04.03.01.001---
Eczema23.03.04.006--
Ejaculation disorder21.03.01.002--
Embolic stroke17.08.01.032; 24.01.04.0100.000545%-
Embolism arterial24.01.01.0140.000091%
Embolism venous24.01.01.0030.000364%-
Emotional disorder19.04.02.0050.008197%-
Endocrine disorder05.09.01.001---
Enlarged clitoris05.05.01.004; 21.08.02.0010.000818%-
Epididymitis11.01.19.005; 21.09.02.001---
Epiphyses premature fusion05.05.03.002; 15.02.02.001---
Erythema23.03.06.001---
Essential hypertension24.08.02.0080.000227%-
Eye disorder06.08.03.001---
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 19 Pages